Chiesi also has DPI candidates in its developmental portfolio ... choosing the best therapy for each patient. "Are dry powder inhalers the key to sustainable respiratory care?" ...

Innovata Biomed Ltd has developed an alternative device, the Clickhaler®, which is a multiple-dose dry powder inhaler (DPI). The present study compared patient acceptability of the salbutamol ...

a Adapted from Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med. 2010; 122:83–93, updated using U.S. Food and Drug Administration.

The results of the ATMOS study showed that a single dose of the drug administered using a dry powder inhaler (DPI) led to a sustained reduction in pulmonary vascular resistance (PVR), a surrogate ...

The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3. ...

In a bid to improve the pharma sector’s drive to cut down greenhouse emissions, several companies are advancing dry powder inhalers (DPIs) for respiratory conditions that are more eco-friendly ...

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and ...